BackgroundAnti-IL-4Rα monoclonal antibodies (mAb) improve lung function and decrease the number of exacerbations in patients with COPD type (T) 2 inflammation. However, the involvement of early innate immune responses underlying these treatment effects is not well known. We sought to understand the effect and mechanisms of IL-4Rα mAb treatment on bronchial epithelial cells from COPD patients under T2 inflammatory conditions with and without rhinoviral infection.MethodsPrimary bronchial epithelial cells (BECs) from healthy and COPD patients were grown at air–liquid interface (ALI) and stimulated with IL-4 or IL-13 cytokines in the presence of IL-4Rα mAb. Cells were infected with human rhinovirus 1B (HRV1B) and collected 24 h after infection. Anti-viral mediators (i.e., interferons (IFN) and pattern recognition receptors (PRR)), as well as chemokine and alarmin expression was measured by RT-qPCR and ELISA.ResultsTreatment with IL-4Rα mAb (100 nM) inhibited eotaxin-3 (CCL26) gene after IL-4/IL-13 induction (p<0.05) in COPD BECs. However, no significant changes in RV-induced IFN-β, PRRs or TSLP gene responses were observed with IL-4/IL-13 stimulation and IL-4Rα mAb treatment. Significant increase in MUC5AC gene expression was observed with both IL-4 and IL-13 stimulation, but it was not reduced with IL-4Rα treatment in BECs.ConclusionsInhibition of IL-4Rα reduced CCL26 levels without affecting anti-viral immune responses in bronchial epithelial cells from COPD patients. Inhibition of IL-4Rα reduced IL-4/IL-13 signaling without broadly suppressing the immune system, which might suggest that inhibition of the IL-4Rα pathways may prevent COPD exacerbations through reduction of eosinophil chemotaxis.
Read full abstract